FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> DNA sequencing | Breast Cancer

Mutation comparison yields cancer insight

Free Newsletter

FierceBiotech IT updates senior biotech, pharma, and IT leaders on how IT advances are shaping clinical trials and clinical research. Get your weekly briefing on clinical trial design and management systems, adaptive trials, eClinical trials, and more. Sign up today!



Tools

Canadian researchers have decoded the genetic structure of metastatic lobular breast cancer by unlocking the 3-billion-letter DNA sequence and identifying mutations that promote the disease's spread. The researchers used DNA sequencing to compare a single patient's lobular breast cancer tumor at two times: when the cancer first presented itself and when it came back nine years later. They found 32 mutations in the latter set and five in the early set, indicating that disease's cause lay within the five. Article


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotechIT Email Newsletter:

More stories about DNA sequencing   Breast Cancer